|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
JP5873656B2
(ja)
|
2011-06-13 |
2016-03-01 |
株式会社Ihi |
金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
SG11201500125QA
(en)
|
2012-07-11 |
2015-02-27 |
Blueprint Medicines Corp |
Inhibitors of the fibroblast growth factor receptor
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
AR094812A1
(es)
|
2013-02-20 |
2015-08-26 |
Eisai R&D Man Co Ltd |
Derivado de piridina monocíclico como inhibidor del fgfr
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
US10124003B2
(en)
*
|
2013-07-18 |
2018-11-13 |
Taiho Pharmaceutical Co., Ltd. |
Therapeutic agent for FGFR inhibitor-resistant cancer
|
|
AU2014291161B2
(en)
*
|
2013-07-18 |
2018-04-26 |
Taiho Pharmaceutical Co., Ltd. |
Antitumor drug for intermittent administration of FGFR inhibitor
|
|
MX360498B
(es)
*
|
2013-08-12 |
2018-11-05 |
Taiho Pharmaceutical Co Ltd |
Compuesto novedoso de pirimidina fusionada o sal del mismo.
|
|
RS63405B1
(sr)
|
2013-10-25 |
2022-08-31 |
Blueprint Medicines Corp |
Inhibitori receptora faktora rasta fibroblasta
|
|
JP6514645B2
(ja)
|
2013-12-27 |
2019-05-15 |
中外製薬株式会社 |
Fgfrゲートキーパー変異遺伝子およびそれを標的とする医薬
|
|
US9695165B2
(en)
|
2014-01-15 |
2017-07-04 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
|
CA2946833C
(en)
*
|
2014-06-24 |
2019-03-05 |
Taiho Pharmaceutical Co., Ltd. |
Pyrrolopyrimidine compounds for prevention of tumors based on nae inhibitory effect
|
|
KR102344105B1
(ko)
|
2014-08-18 |
2021-12-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
모노시클릭 피리딘 유도체의 염 및 이의 결정
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
CN105837575B
(zh)
*
|
2015-01-13 |
2019-01-15 |
四川大学 |
3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
|
|
TR201910158T4
(tr)
*
|
2015-01-30 |
2019-07-22 |
Taiho Pharmaceutical Co Ltd |
İmmün hastalıklara yönelik önleyici ve/veya terapötik ajan.
|
|
TWI712601B
(zh)
|
2015-02-20 |
2020-12-11 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
EP3275442B1
(en)
|
2015-03-25 |
2021-07-28 |
National Cancer Center |
Therapeutic agent for bile duct cancer
|
|
PT3279202T
(pt)
|
2015-03-31 |
2020-08-31 |
Taiho Pharmaceutical Co Ltd |
Cristal de composto de alquinilo de benzeno 3,5-dissubstituído
|
|
JP6762300B2
(ja)
|
2015-06-17 |
2020-09-30 |
中外製薬株式会社 |
アミノピラゾール誘導体
|
|
JP6141568B1
(ja)
|
2015-09-01 |
2017-06-07 |
大鵬薬品工業株式会社 |
新規なピラゾロ[3,4−d]ピリミジン化合物又はその塩
|
|
CN108367000A
(zh)
|
2015-12-17 |
2018-08-03 |
卫材R&D管理有限公司 |
用于乳腺癌的治疗剂
|
|
TWI623316B
(zh)
*
|
2015-12-22 |
2018-05-11 |
Taiho Pharmaceutical Co Ltd |
Antitumor effect enhancer derived from pyrrolopyrimidine compound
|
|
CA3015484C
(en)
*
|
2016-02-23 |
2022-11-08 |
Taiho Pharmaceutical Co., Ltd. |
Novel condensed pyrimidine compound or salt thereof
|
|
EP3424505A4
(en)
|
2016-03-04 |
2019-10-16 |
Taiho Pharmaceutical Co., Ltd. |
PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
|
|
US11883404B2
(en)
|
2016-03-04 |
2024-01-30 |
Taiho Pharmaceuticals Co., Ltd. |
Preparation and composition for treatment of malignant tumors
|
|
CN107344940B
(zh)
*
|
2016-05-06 |
2020-04-21 |
广东东阳光药业有限公司 |
Btk抑制剂及其用途
|
|
CN107698593A
(zh)
*
|
2016-08-09 |
2018-02-16 |
南京天印健华医药科技有限公司 |
作为fgfr抑制剂的杂环化合物
|
|
WO2018159613A1
(ja)
*
|
2017-02-28 |
2018-09-07 |
大鵬薬品工業株式会社 |
ピラゾロ[3,4-d]ピリミジン化合物を用いた抗腫瘍効果増強剤
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
KR20190043437A
(ko)
|
2017-10-18 |
2019-04-26 |
씨제이헬스케어 주식회사 |
단백질 키나제 억제제로서의 헤테로고리 화합물
|
|
CN109776544B
(zh)
*
|
2017-11-15 |
2022-02-01 |
上海医药工业研究院 |
吡唑并[3,4-d]嘧啶类化合物及其制备方法和用途
|
|
JP6918204B2
(ja)
|
2018-03-19 |
2021-08-11 |
大鵬薬品工業株式会社 |
アルキル硫酸ナトリウムを含む医薬組成物
|
|
US11219619B2
(en)
|
2018-03-28 |
2022-01-11 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for hepatocellular carcinoma
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
JP7162372B2
(ja)
|
2018-07-02 |
2022-10-28 |
深▲チェン▼市塔吉瑞生物医薬有限公司 |
キナーゼ活性を阻害するためのアルキニル(ヘテロ)芳香族化合物
|
|
KR102742083B1
(ko)
|
2018-11-09 |
2024-12-16 |
다이호야쿠힌고교 가부시키가이샤 |
디메톡시벤젠 화합물의 제조 방법
|
|
US20210388002A1
(en)
*
|
2018-11-09 |
2021-12-16 |
Taiho Pharmaceutical Co., Ltd. |
Dimethoxybenzene compound analogs, methods for analyzing said compounds and standard products of said compounds
|
|
KR102195348B1
(ko)
|
2018-11-15 |
2020-12-24 |
에이치케이이노엔 주식회사 |
단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
|
|
WO2020110974A1
(ja)
|
2018-11-26 |
2020-06-04 |
大鵬薬品工業株式会社 |
線維芽細胞増殖因子受容体阻害剤と内分泌療法との併用による内分泌療法が適用される腫瘍の治療及び予防方法
|
|
WO2020170355A1
(ja)
*
|
2019-02-20 |
2020-08-27 |
大鵬薬品工業株式会社 |
Fgfr1変異腫瘍の治療方法
|
|
KR20210131387A
(ko)
*
|
2019-02-28 |
2021-11-02 |
다이호야쿠힌고교 가부시키가이샤 |
3,5-2치환 벤젠알키닐 화합물과 펨브롤리주맙을 사용한 암 치료법
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
|
WO2020231990A1
(en)
*
|
2019-05-13 |
2020-11-19 |
Relay Therapeutics, Inc. |
Fgfr inhibitors and methods of use thereof
|
|
EP3969442A4
(en)
*
|
2019-05-17 |
2023-08-02 |
Kinnate Biopharma Inc. |
FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS
|
|
KR20220024821A
(ko)
|
2019-06-21 |
2022-03-03 |
다이호야쿠힌고교 가부시키가이샤 |
악성 종양의 치료 방법
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3157361A1
(en)
|
2019-10-14 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CN114641293B
(zh)
*
|
2019-11-08 |
2024-05-31 |
石药集团中奇制药技术(石家庄)有限公司 |
一种fgfr抑制剂的用途
|
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Fgfr阻害剤の誘導体
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
TWI857207B
(zh)
|
2020-01-31 |
2024-10-01 |
國立大學法人京都大學 |
軟骨發育異常症之治療
|
|
US11345681B1
(en)
|
2020-06-05 |
2022-05-31 |
Kinnate Biopharma Inc. |
Inhibitors of fibroblast growth factor receptor kinases
|
|
EP4183395A4
(en)
*
|
2020-07-15 |
2024-07-24 |
Taiho Pharmaceutical Co., Ltd. |
PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
|
|
TWI797711B
(zh)
*
|
2020-08-13 |
2023-04-01 |
大陸商上海和譽生物醫藥科技有限公司 |
一種fgfr及其突變抑制劑,其製備方法和應用
|
|
WO2022042613A1
(zh)
*
|
2020-08-27 |
2022-03-03 |
上海和誉生物医药科技有限公司 |
一种1h-吡唑-4-酰胺衍生物,其制备方法和应用
|
|
TW202233625A
(zh)
*
|
2020-11-18 |
2022-09-01 |
美商傳達治療有限公司 |
Fgfr抑制劑及其製造及使用方法
|
|
TWI911331B
(zh)
*
|
2020-11-20 |
2026-01-11 |
日商大鵬藥品工業股份有限公司 |
以縮合嘧啶化合物作為有效成分之腦移行性腫瘤治療劑
|
|
CN114805359B
(zh)
*
|
2021-01-28 |
2023-10-27 |
药雅科技(上海)有限公司 |
炔代杂环化合物fgfr抑制剂的制备方法和用途
|
|
CN115028634B
(zh)
*
|
2021-03-08 |
2023-11-28 |
药雅科技(上海)有限公司 |
一种炔代吡嗪并杂环类fgfr抑制剂及其制备方法和用途
|
|
JP2024509472A
(ja)
*
|
2021-03-08 |
2024-03-01 |
大鵬薬品工業株式会社 |
Fgfr2及び癌ドライバー遺伝子に遺伝子変化が同時発生する患者におけるがんの治療
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
CN115785103A
(zh)
*
|
2022-12-28 |
2023-03-14 |
北京康立生医药技术开发有限公司 |
一种治疗胆管癌药物福巴替尼的合成方法
|
|
WO2025046898A1
(ja)
|
2023-08-31 |
2025-03-06 |
大鵬薬品工業株式会社 |
3,5-二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬を含む癌治療法
|
|
WO2025178019A1
(ja)
*
|
2024-02-19 |
2025-08-28 |
国立大学法人大阪大学 |
繊毛病治療用医薬組成物
|
|
CN119080780A
(zh)
*
|
2024-08-29 |
2024-12-06 |
武汉九州钰民医药科技有限公司 |
一种富替巴替尼的制备方法
|
|
CN120172981B
(zh)
*
|
2025-05-20 |
2025-07-25 |
南京工业大学 |
一类以fgfr2为靶点的小分子降解剂及其药物组合物和应用
|